Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Elizabeth Robins Gerstner, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA244975 (GERSTNER, ELIZABETH) Dec 15, 2019 - Nov 30, 2024
    NIH/NCI
    Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases
    Role: Principal Investigator
  2. R01CA211238 (GERSTNER, ELIZABETH) Sep 19, 2017 - Aug 31, 2020
    NIH/NCI
    Evaluation of metastatic brain tumor heterogeneity and physiological response to immunotherapy using advanced MRI
    Role: Principal Investigator
  3. K23CA169021 (GERSTNER, ELIZABETH) Jun 1, 2014 - May 31, 2019
    NIH/NCI
    Evaluation of impact of anti-VEGF drugs on concomitant chemotherapy in GBM
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Beers A, Brown J, Chang K, Hoebel K, Patel J, Ly KI, Tolaney SM, Brastianos P, Rosen B, Gerstner ER, Kalpathy-Cramer J. DeepNeuro: an open-source deep learning toolbox for neuroimaging. Neuroinformatics. 2020 Jun 23. PMID: 32578020.
    Citations:    
  2. Brastianos PK, Lee EQ, Cohen JV, Tolaney SM, Lin NU, Wang N, Chukwueke U, White MD, Nayyar N, Kim A, Alvarez-Breckenridge C, Krop I, Mahar MK, Bertalan MS, Shaw B, Mora JL, Goss N, Subramanian M, Nayak L, Dietrich J, Forst DA, Nahed BV, Batchelor TT, Shih HA, Gerstner ER, Moy B, Lawrence D, Giobbie-Hurder A, Carter SL, Oh K, Cahill DP, Sullivan RJ. Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 Jun 18. PMID: 32555425.
    Citations:    
  3. Boxerman JL, Quarles CC, Hu LS, Erickson BJ, Gerstner ER, Smits M, Kaufmann TJ, Barboriak DP, Huang RH, Wick W, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Chung C, van den Bent MJ, Chang S, Al Yung WK, Cloughesy TF, Wen PY, Gilbert MR, Rosen BR, Ellingson BM, Schmainda KM. Consensus Recommendations for a Dynamic Susceptibility Contrast MRI Protocol for Use in High-Grade Gliomas. Neuro Oncol. 2020 Jun 09. PMID: 32516388.
    Citations:    
  4. Kaufmann TJ, Smits M, Boxerman J, Huang R, Barboriak DP, Weller M, Chung C, Tsien C, Brown PD, Shankar L, Galanis E, Gerstner E, van den Bent MJ, Burns TC, Parney IF, Dunn G, Brastianos PK, Lin NU, Wen PY, Ellingson BM. Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro Oncol. 2020 Jun 09; 22(6):757-772. PMID: 32048719.
    Citations:    
  5. Brastianos PK, Lee EQ, Cohen JV, Tolaney SM, Lin NU, Wang N, Chukwueke U, White MD, Nayyar N, Kim A, Alvarez-Breckenridge C, Krop I, Mahar MK, Bertalan MS, Shaw B, Mora JL, Goss N, Subramanian M, Nayak L, Dietrich J, Forst DA, Nahed BV, Batchelor TT, Shih HA, Gerstner ER, Moy B, Lawrence D, Giobbie-Hurder A, Carter SL, Oh K, Cahill DP, Sullivan RJ. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 Jun 02. PMID: 32483359.
    Citations:    
  6. Huang RY, Young RJ, Ellingson BM, Veeraraghavan H, Wang W, Tixier F, Um H, Nawaz R, Luks T, Kim J, Gerstner ER, Schiff D, Peters KB, Mellinghoff IK, Chang S, Cloughesy TF, Wen PY. Volumetric Analysis of IDH-Mutant Lower-Grade Glioma: A Natural History Study of Tumor Growth Rates Before and After Treatment. Neuro Oncol. 2020 Apr 24. PMID: 32328652.
    Citations:    
  7. Ellingson BM, Yao J, Raymond C, Nathanson DA, Chakhoyan A, Simpson J, Garner JS, Olivero AG, Mueller LU, Rodon J, Gerstner E, Cloughesy TF, Wen PY. Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma. Clin Cancer Res. 2020 Apr 08. PMID: 32269051.
    Citations:    
  8. Shih DJH, Nayyar N, Bihun I, Dagogo-Jack I, Gill CM, Aquilanti E, Bertalan M, Kaplan A, D'Andrea MR, Chukwueke U, Ippen FM, Alvarez-Breckenridge C, Camarda ND, Lastrapes M, McCabe D, Kuter B, Kaufman B, Strickland MR, Martinez-Gutierrez JC, Nagabhushan D, De Sauvage M, White MD, Castro BA, Hoang K, Kaneb A, Batchelor ED, Paek SH, Park SH, Martinez-Lage M, Berghoff AS, Merrill P, Gerstner ER, Batchelor TT, Frosch MP, Frazier RP, Borger DR, Iafrate AJ, Johnson BE, Santagata S, Preusser M, Cahill DP, Carter SL, Brastianos PK. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020 04; 52(4):371-377. PMID: 32203465.
    Citations:    
  9. Lee EQ, Zhang P, Wen PY, Gerstner ER, Reardon DA, Aldape KD, deGroot JF, Pan E, Raizer JJ, Kim LJ, Chmura SJ, Robins HI, Connelly JM, Battiste JD, Villano JL, Wagle N, Merrell RT, Wendland MM, Mehta MP. NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020 Jun 15; 126(12):2821-2828. PMID: 32154928.
    Citations:    
  10. Choi BD, Gerstner ER, Curry WT. A Common Rule for Resection of Glioblastoma in the Molecular Era. JAMA Oncol. 2020 Feb 06. PMID: 32027348.
    Citations:    
  11. Wen PY, Cloughesy TF, Olivero AG, Morrissey KM, Wilson TR, Lu X, Mueller LU, Coimbra AF, Ellingson BM, Gerstner E, Lee EQ, Rodon J. First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. Clin Cancer Res. 2020 Apr 15; 26(8):1820-1828. PMID: 31937616.
    Citations:    
  12. Chang K, Beers AL, Bai HX, Brown JM, Ly KI, Li X, Senders JT, Kavouridis VK, Boaro A, Su C, Bi WL, Rapalino O, Liao W, Shen Q, Zhou H, Xiao B, Wang Y, Zhang PJ, Pinho MC, Wen PY, Batchelor TT, Boxerman JL, Arnaout O, Rosen BR, Gerstner ER, Yang L, Huang RY, Kalpathy-Cramer J. Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement. Neuro Oncol. 2019 11 04; 21(11):1412-1422. PMID: 31190077.
    Citations:    
  13. Gerstner ER, Emblem KE, Chang K, Vakulenko-Lagun B, Yen YF, Beers AL, Dietrich J, Plotkin SR, Catana C, Hooker JM, Duda DG, Rosen B, Kalpathy-Cramer J, Jain RK, Batchelor T. Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. Clin Cancer Res. 2020 01 01; 26(1):206-212. PMID: 31558474.
    Citations:    
  14. Leone JP, Duda DG, Hu J, Barry WT, Trippa L, Gerstner ER, Jain RK, Tan S, Lawler E, Winer EP, Lin NU, Tolaney SM. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat. 2020 Jan; 179(1):113-123. PMID: 31541381.
    Citations:    
  15. Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER. Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2019 Jun 14; 9(1):8721. PMID: 31197238.
    Citations:    
  16. Gerstner ER. Dose diversification in newly diagnosed glioblastoma. Neuro Oncol. 2019 06 10; 21(6):701-702. PMID: 30957855.
    Citations:    
  17. Seano G, Nia HT, Emblem KE, Datta M, Ren J, Krishnan S, Kloepper J, Pinho MC, Ho WW, Ghosh M, Askoxylakis V, Ferraro GB, Riedemann L, Gerstner ER, Batchelor TT, Wen PY, Lin NU, Grodzinsky AJ, Fukumura D, Huang P, Baish JW, Padera TP, Munn LL, Jain RK. Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. Nat Biomed Eng. 2019 03; 3(3):230-245. PMID: 30948807.
    Citations:    
  18. Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER. Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2018 11 20; 8(1):17062. PMID: 30459364.
    Citations:    Fields:    
  19. Ou Y, Zöllei L, Da X, Retzepi K, Murphy SN, Gerstner ER, Rosen BR, Grant PE, Kalpathy-Cramer J, Gollub RL. Field of View Normalization in Multi-Site Brain MRI. Neuroinformatics. 2018 10; 16(3-4):431-444. PMID: 29353341.
    Citations:    Fields:    
  20. Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250. PMID: 29660006.
    Citations: 1     Fields:    
  21. Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, Mankoff DA, Kinahan PE, Linden HM, Lambin P, Dilling TJ, Rubin DL, Hadjiiski L, Buatti JM. The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1219-1235. PMID: 29966725.
    Citations:    Fields:    
  22. Lee EQ, Duda DG, Muzikansky A, Gerstner ER, Kuhn JG, Reardon DA, Nayak L, Norden AD, Doherty L, LaFrankie D, Stefanik J, Vardam T, Smith KH, McCluskey C, Gaffey S, Batchelor TT, Jain RK, Wen PY. Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clin Cancer Res. 2018 10 01; 24(19):4643-4649. PMID: 29941486.
    Citations:    Fields:    
  23. Ly KI, Gerstner ER. The Role of Advanced Brain Tumor Imaging in the Care of Patients with Central Nervous System Malignancies. Curr Treat Options Oncol. 2018 06 21; 19(8):40. PMID: 29931476.
    Citations:    Fields:    
  24. Ratai EM, Zhang Z, Fink J, Muzi M, Hanna L, Greco E, Richards T, Kim D, Andronesi OC, Mintz A, Kostakoglu L, Prah M, Ellingson B, Schmainda K, Sorensen G, Barboriak D, Mankoff D, Gerstner ER. ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. PLoS One. 2018; 13(6):e0198548. PMID: 29902200.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  25. Sastry RA, Shankar GM, Gerstner ER, Curry WT. The impact of surgery on survival after progression of glioblastoma: A retrospective cohort analysis of a contemporary patient population. J Clin Neurosci. 2018 Jul; 53:41-47. PMID: 29680441.
    Citations:    Fields:    Translation:Humans
  26. Andronesi OC, Arrillaga-Romany IC, Ly KI, Bogner W, Ratai EM, Reitz K, Iafrate AJ, Dietrich J, Gerstner ER, Chi AS, Rosen BR, Wen PY, Cahill DP, Batchelor TT. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun. 2018 04 16; 9(1):1474. PMID: 29662077.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  27. Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY. Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol. 2018 03 27; 20(4):546-556. PMID: 29016887.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  28. Gerstner ER, Pajtler KW. Ependymoma. Semin Neurol. 2018 02; 38(1):104-111. PMID: 29548057.
    Citations:    Fields:    Translation:Humans
  29. Prust ML, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, Batchelor TT, Gerstner ER, Dietrich J. Standard chemoradiation in combination with VEGF targeted therapy for glioblastoma results in progressive gray and white matter volume loss. Neuro Oncol. 2018 01 22; 20(2):289-291. PMID: 29315410.
    Citations:    Fields:    Translation:Humans
  30. Reardon DA, Lassman AB, Schiff D, Yunus SA, Gerstner ER, Cloughesy TF, Lee EQ, Gaffey SC, Barrs J, Bruno J, Muzikansky A, Duda DG, Jain RK, Wen PY. Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer. 2018 04 01; 124(7):1438-1448. PMID: 29266174.
    Citations: 4     Fields:    
  31. Chang K, Bai HX, Zhou H, Su C, Bi WL, Agbodza E, Kavouridis VK, Senders JT, Boaro A, Beers A, Zhang B, Capellini A, Liao W, Shen Q, Li X, Xiao B, Cryan J, Ramkissoon S, Ramkissoon L, Ligon K, Wen PY, Bindra RS, Woo J, Arnaout O, Gerstner ER, Zhang PJ, Rosen BR, Yang L, Huang RY, Kalpathy-Cramer J. Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging. Clin Cancer Res. 2018 03 01; 24(5):1073-1081. PMID: 29167275.
    Citations: 5     Fields:    
  32. Brastianos PK, Nayyar N, Rosebrock D, Leshchiner I, Gill CM, Livitz D, Bertalan MS, D'Andrea M, Hoang K, Aquilanti E, Chukwueke UN, Kaneb A, Chi A, Plotkin S, Gerstner ER, Frosch MP, Suva ML, Cahill DP, Getz G, Batchelor TT. Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. NPJ Precis Oncol. 2017; 1(1):33. PMID: 29872714.
    Citations: 1     
  33. Gerstner ER. ACT IV: the final act for rindopepimut? Lancet Oncol. 2017 10; 18(10):1294-1296. PMID: 28844498.
    Citations: 1     Fields:    Translation:Humans
  34. Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res. 2017 Oct 01; 23(19):5745-5756. PMID: 28655794.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  35. David WS, Bowley MP, Mehan WA, Shin JH, Gerstner ER, DeWitt JC. Case 19-2017 - A 53-Year-Old Woman with Leg Numbness and Weakness. N Engl J Med. 2017 Jun 22; 376(25):2471-2481. PMID: 28636859.
    Citations:    Fields:    Translation:Humans
  36. Andronesi OC, Esmaeili M, Borra RJH, Emblem K, Gerstner ER, Pinho MC, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Ivy SP, Wen PY, Duda DG, Jain R, Rosen BR, Sorensen GA, Batchelor TT. Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol. 2017; 1. PMID: 29202103.
    Citations:    
  37. Gerstner ER. MRI and PET: Noninvasive Tools to Probe the Biology of Diffuse Intrinsic Pontine Glioma. J Nucl Med. 2017 08; 58(8):1262-1263. PMID: 28385794.
    Citations:    Fields:    Translation:Humans
  38. Batchelor TT, Gerstner ER, Ye X, Desideri S, Duda DG, Peereboom D, Lesser GJ, Chowdhary S, Wen PY, Grossman S, Supko JG. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-ß tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro Oncol. 2017 04 01; 19(4):567-575. PMID: 27663390.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  39. Kurland BF, Aggarwal S, Yankeelov TE, Gerstner ER, Mountz JM, Linden HM, Jones EF, Bodeker KL, Buatti JM. Accrual Patterns for Clinical Studies Involving Quantitative Imaging: Results of an NCI Quantitative Imaging Network (QIN) Survey. Tomography. 2016 Dec; 2(4):276-282. PMID: 28127586.
    Citations:    
  40. Hansen MB, Tietze A, Kalpathy-Cramer J, Gerstner ER, Batchelor TT, Østergaard L, Mouridsen K. Reliable estimation of microvascular flow patterns in patients with disrupted blood-brain barrier using dynamic susceptibility contrast MRI. J Magn Reson Imaging. 2017 08; 46(2):537-549. PMID: 27902858.
    Citations: 2     Fields:    Translation:Humans
  41. Kalpathy-Cramer J, Chandra V, Da X, Ou Y, Emblem KE, Muzikansky A, Cai X, Douw L, Evans JG, Dietrich J, Chi AS, Wen PY, Stufflebeam S, Rosen B, Duda DG, Jain RK, Batchelor TT, Gerstner ER. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. J Neurooncol. 2017 02; 131(3):603-610. PMID: 27853960.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  42. Le M, Delingette H, Kalpathy-Cramer J, Gerstner ER, Batchelor T, Unkelbach J, Ayache N. Personalized Radiotherapy Planning Based on a Computational Tumor Growth Model. IEEE Trans Med Imaging. 2016 Nov 08. PMID: 27845656.
    Citations:    
  43. Le M, Delingette H, Kalpathy-Cramer J, Gerstner ER, Batchelor T, Unkelbach J, Ayache N. Personalized Radiotherapy Planning Based on a Computational Tumor Growth Model. IEEE Trans Med Imaging. 2017 03; 36(3):815-825. PMID: 28113925.
    Citations:    Fields:    Translation:Humans
  44. Boujelben A, Watson M, McDougall S, Yen YF, Gerstner ER, Catana C, Deisboeck T, Batchelor TT, Boas D, Rosen B, Kalpathy-Cramer J, Chaplain MA. Multimodality imaging and mathematical modelling of drug delivery to glioblastomas. Interface Focus. 2016 Oct 06; 6(5):20160039. PMID: 27708763.
    Citations: 2     
  45. Ohnishi T, Nakamura Y, Tanaka T, Tanaka T, Hashimoto N, Haneishi H, Batchelor TT, Gerstner ER, Taylor JW, Snuderl M, Yagi Y. Deformable image registration between pathological images and MR image via an optical macro image. Pathol Res Pract. 2016 Oct; 212(10):927-936. PMID: 27613662.
    Citations: 1     Fields:    Translation:Humans
  46. Jafari-Khouzani K, Loebel F, Bogner W, Rapalino O, Gonzalez GR, Gerstner E, Chi AS, Batchelor TT, Rosen BR, Unkelbach J, Shih HA, Cahill DP, Andronesi OC. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. Neuro Oncol. 2016 11; 18(11):1569-1578. PMID: 27382115.
    Citations: 5     Fields:    Translation:Humans
  47. Gerstner ER, Zhang Z, Fink JR, Muzi M, Hanna L, Greco E, Prah M, Schmainda KM, Mintz A, Kostakoglu L, Eikman EA, Ellingson BM, Ratai EM, Sorensen AG, Barboriak DP, Mankoff DA. ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI. Clin Cancer Res. 2016 Oct 15; 22(20):5079-5086. PMID: 27185374.
    Citations: 12     Fields:    Translation:Humans
  48. Le M, Delingette H, Kalpathy-Cramer J, Gerstner ER, Batchelor T, Unkelbach J, Ayache N. MRI Based Bayesian Personalization of a Tumor Growth Model. IEEE Trans Med Imaging. 2016 10; 35(10):2329-2339. PMID: 27164582.
    Citations: 2     Fields:    Translation:Humans
  49. Le M, Delingette H, Kalpathy-Cramer J, Gerstner E, Batchelor T, Unkelbach J, Ayache N. MRI Based Bayesian Personalization of a Tumor Growth Model. IEEE Trans Med Imaging. 2016 Apr 29. PMID: 28113549.
    Citations:    
  50. Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, Jacobs MA, Jain RK, Zalewski C, Dombi E, Widemann BC, Plotkin SR. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. J Clin Oncol. 2016 05 10; 34(14):1669-75. PMID: 26976425.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  51. Curry WT, Gorrepati R, Piesche M, Sasada T, Agarwalla P, Jones PS, Gerstner ER, Golby AJ, Batchelor TT, Wen PY, Mihm MC, Dranoff G. Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. Clin Cancer Res. 2016 06 15; 22(12):2885-96. PMID: 26873960.
    Citations: 4     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
  52. Jordan JT, Gerstner ER, Batchelor TT, Cahill DP, Plotkin SR. Glioblastoma care in the elderly. Cancer. 2016 Jan 15; 122(2):189-97. PMID: 26618888.
    Citations: 12     Fields:    Translation:Humans
  53. Andronesi OC, Loebel F, Bogner W, Marjanska M, Vander Heiden MG, Iafrate AJ, Dietrich J, Batchelor TT, Gerstner ER, Kaelin WG, Chi AS, Rosen BR, Cahill DP. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clin Cancer Res. 2016 Apr 01; 22(7):1632-41. PMID: 26534967.
    Citations: 24     Fields:    Translation:Humans
  54. Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015 Sep; 17(9):1188-98. PMID: 26250565.
    Citations: 49     Fields:    Translation:Humans
  55. Prust MJ, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, Batchelor TT, Gerstner ER, Dietrich J. Standard chemoradiation for glioblastoma results in progressive brain volume loss. Neurology. 2015 Aug 25; 85(8):683-91. PMID: 26208964.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  56. Gerstner ER, Emblem KE, Sorensen GA. Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapy--Are We There Yet? Cancer J. 2015 Jul-Aug; 21(4):337-42. PMID: 26222087.
    Citations: 2     Fields:    Translation:Humans
  57. Prah MA, Stufflebeam SM, Paulson ES, Kalpathy-Cramer J, Gerstner ER, Batchelor TT, Barboriak DP, Rosen BR, Schmainda KM. Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma. AJNR Am J Neuroradiol. 2015 Sep; 36(9):1654-61. PMID: 26066626.
    Citations: 3     Fields:    Translation:Humans
  58. Jafari-Khouzani K, Emblem KE, Kalpathy-Cramer J, Bjørnerud A, Vangel MG, Gerstner ER, Schmainda KM, Paynabar K, Wu O, Wen PY, Batchelor T, Rosen B, Stufflebeam SM. Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients. Transl Oncol. 2015 Jun; 8(3):137-46. PMID: 26055170.
    Citations: 5     
  59. Gerstner ER, Ye X, Duda DG, Levine MA, Mikkelsen T, Kaley TJ, Olson JJ, Nabors BL, Ahluwalia MS, Wen PY, Jain RK, Batchelor TT, Grossman S. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1386-92. PMID: 26008604.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  60. Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol. 2015 Apr 01; 33(10):1197-213. PMID: 25713439.
    Citations: 36     Fields:    Translation:Humans
  61. Chheda MG, Wen PY, Hochberg FH, Chi AS, Drappatz J, Eichler AF, Yang D, Beroukhim R, Norden AD, Gerstner ER, Betensky RA, Batchelor TT. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. J Neurooncol. 2015 Feb; 121(3):627-34. PMID: 25503302.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  62. Menze BH, Jakab A, Bauer S, Kalpathy-Cramer J, Farahani K, Kirby J, Burren Y, Porz N, Slotboom J, Wiest R, Lanczi L, Gerstner E, Weber MA, Arbel T, Avants BB, Ayache N, Buendia P, Collins DL, Cordier N, Corso JJ, Criminisi A, Das T, Delingette H, Demiralp Ç, Durst CR, Dojat M, Doyle S, Festa J, Forbes F, Geremia E, Glocker B, Golland P, Guo X, Hamamci A, Iftekharuddin KM, Jena R, John NM, Konukoglu E, Lashkari D, Mariz JA, Meier R, Pereira S, Precup D, Price SJ, Raviv TR, Reza SM, Ryan M, Sarikaya D, Schwartz L, Shin HC, Shotton J, Silva CA, Sousa N, Subbanna NK, Szekely G, Taylor TJ, Thomas OM, Tustison NJ, Unal G, Vasseur F, Wintermark M, Ye DH, Zhao L, Zhao B, Zikic D, Prastawa M, Reyes M, Van Leemput K. The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS). IEEE Trans Med Imaging. 2015 Oct; 34(10):1993-2024. PMID: 25494501.
    Citations: 82     Fields:    Translation:Humans
  63. Taylor JW, Dietrich J, Gerstner ER, Norden AD, Rinne ML, Cahill DP, Stemmer-Rachamimov A, Wen PY, Betensky RA, Giorgio DH, Snodgrass K, Randall AE, Batchelor TT, Chi AS. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol. 2015 Feb; 121(3):557-63. PMID: 25411098.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  64. Gerstner ER. Is a picture really worth a 1000 words? Neuro Oncol. 2014 Dec; 16(12):1563-4. PMID: 25326497.
    Citations:    Fields:    Translation:Humans
  65. Kalpathy-Cramer J, Gerstner ER, Emblem KE, Andronesi O, Rosen B. Advanced magnetic resonance imaging of the physical processes in human glioblastoma. Cancer Res. 2014 Sep 01; 74(17):4622-4637. PMID: 25183787.
    Citations: 28     Fields:    Translation:Humans
  66. Emblem KE, Farrar CT, Gerstner ER, Batchelor TT, Borra RJ, Rosen BR, Sorensen AG, Jain RK. Vessel caliber--a potential MRI biomarker of tumour response in clinical trials. Nat Rev Clin Oncol. 2014 Oct; 11(10):566-84. PMID: 25113840.
    Citations: 18     Fields:    Translation:Humans
  67. Loebel F, Cahill DP, Bogner W, Marjanska M, Gerstner E, Batchelor T, Rosen BR, Chi AS, Andronesi OC. Sherry apple resident travel scholarship 194 assessment of treatment response in isocitrate dehydrogenase-mutant gliomas by quantification of 2-hydroxyglutarate with in vivo 3-dimensional magnetic resonance spectroscopy. Neurosurgery. 2014 Aug; 61 Suppl 1:224. PMID: 25032645.
    Citations:    
  68. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen B, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii12. PMID: 25165209.
    Citations:    
  69. Poynton CB, Chen KT, Chonde DB, Izquierdo-Garcia D, Gollub RL, Gerstner ER, Batchelor TT, Catana C. Probabilistic atlas-based segmentation of combined T1-weighted and DUTE MRI for calculation of head attenuation maps in integrated PET/MRI scanners. Am J Nucl Med Mol Imaging. 2014; 4(2):160-71. PMID: 24753982.
    Citations: 13     
  70. Reuter M, Gerstner ER, Rapalino O, Batchelor TT, Rosen B, Fischl B. Impact of MRI head placement on glioma response assessment. J Neurooncol. 2014 May; 118(1):123-9. PMID: 24566765.
    Citations: 12     Fields:    Translation:Humans
  71. Pinho MC, Polaskova P, Kalpathy-Cramer J, Jennings D, Emblem KE, Jain RK, Rosen BR, Wen PY, Sorensen AG, Batchelor TT, Gerstner ER. Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. Oncologist. 2014 Jan; 19(1):75-81. PMID: 24309981.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  72. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64. PMID: 24190997.
    Citations: 100     Fields:    Translation:HumansCTClinical Trials
  73. Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, Sorensen AG, Rosen BR. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest. 2013 Sep; 123(9):3659-63. PMID: 23999439.
    Citations: 39     Fields:    Translation:Humans
  74. Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov AO, Batchelor TT, Jain RK. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013 Aug; 15(8):1079-87. PMID: 23828240.
    Citations: 44     Fields:    Translation:HumansCells
  75. Taylor J, Gerstner ER. Anti-angiogenic therapy in high-grade glioma (treatment and toxicity). Curr Treat Options Neurol. 2013 Jun; 15(3):328-37. PMID: 23417315.
    Citations: 3     
  76. Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013 Jan 31; 121(5):745-51. PMID: 23197589.
    Citations: 29     Fields:    Translation:HumansCTClinical Trials
  77. Kurland BF, Gerstner ER, Mountz JM, Schwartz LH, Ryan CW, Graham MM, Buatti JM, Fennessy FM, Eikman EA, Kumar V, Forster KM, Wahl RL, Lieberman FS. Promise and pitfalls of quantitative imaging in oncology clinical trials. Magn Reson Imaging. 2012 Nov; 30(9):1301-12. PMID: 22898682.
    Citations: 21     Fields:    Translation:HumansCells
  78. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, Vander Heiden MG, Sorensen AG. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012 Jan 11; 4(116):116ra4. PMID: 22238332.
    Citations: 102     Fields:    Translation:Humans
  79. Gerstner ER, Batchelor TT. Antiangiogenic therapy for glioblastoma. Cancer J. 2012 Jan-Feb; 18(1):45-50. PMID: 22290257.
    Citations: 17     Fields:    Translation:Humans
  80. Gerstner ER, Sorensen AG. Diffusion and diffusion tensor imaging in brain cancer. Semin Radiat Oncol. 2011 Apr; 21(2):141-6. PMID: 21356481.
    Citations: 15     Fields:    Translation:Humans
  81. Barnard ZR, Agarwalla PK, Jeyaretna DS, Farrell CJ, Gerstner ER, Tian D, Curry WT. Sporadic primary malignant intracerebral nerve sheath tumors: case report and literature review. J Neurooncol. 2011 Sep; 104(2):605-10. PMID: 21327709.
    Citations: 4     Fields:    Translation:Humans
  82. Gerstner ER, Batchelor TT. Imaging and response criteria in gliomas. Curr Opin Oncol. 2010 Nov; 22(6):598-603. PMID: 20689430.
    Citations: 4     Fields:    Translation:HumansAnimals
  83. Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011 Jun; 103(2):325-32. PMID: 20821342.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  84. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23. PMID: 20458050.
    Citations: 168     Fields:    Translation:HumansCTClinical Trials
  85. Gerstner ER, Batchelor TT. Primary central nervous system lymphoma. Arch Neurol. 2010 Mar; 67(3):291-7. PMID: 20212226.
    Citations: 38     Fields:    Translation:Humans
  86. Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, Sorensen G. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. 2010 May; 12(5):466-72. PMID: 20406897.
    Citations: 50     Fields:    Translation:HumansCTClinical Trials
  87. Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol. 2010 Feb 20; 28(6):e91-3. PMID: 19933906.
    Citations: 41     Fields:    Translation:Humans
  88. Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, Batchelor TT. Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology. 2009 Nov 03; 73(18):1509-10. PMID: 19884580.
    Citations: 34     Fields:    Translation:HumansCells
  89. Chi AS, Gerstner ER, Eichler AF, Chea HK, Drappatz J, Wen PY, Ivy SP, Loeffler JS, Sorensen AG, Jain RK, Batchelor TT. Phase Ib study of cediranib in combination with daily temozolomide and radiation in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13010. PMID: 27962847.
    Citations:    
  90. Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, Batchelor TT. MGMT methylation status may predict survival in elderly patients with newly diagnosed glioblastoma (GBM). J Clin Oncol. 2009 May 20; 27(15_suppl):e13023. PMID: 27962794.
    Citations:    
  91. Batchelor T, Eichler AF, Plotkin SR, Drappatz J, Wen P, Sorensen AG, Gerstner E. Phase I trial of vatalanib (PTK787) in combination with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2035. PMID: 27964624.
    Citations:    
  92. Gerstner ER, Sorensen AG, Jain RK, Batchelor TT. Anti-vascular endothelial growth factor therapy for malignant glioma. Curr Neurol Neurosci Rep. 2009 May; 9(3):254-62. PMID: 19348715.
    Citations: 2     Fields:    Translation:HumansCells
  93. Gerstner ER, Duda DG, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, Ivy P, Jain RK, Batchelor TT. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol. 2009 Apr; 6(4):229-36. PMID: 19333229.
    Citations: 56     Fields:    Translation:Humans
  94. Gerstner ER, McNamara MB, Norden AD, Lafrankie D, Wen PY. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol. 2009 Aug; 94(1):97-101. PMID: 19221865.
    Citations: 39     Fields:    Translation:Humans
  95. A. S. Chi, E. R. Gerstner, A. F. Eichler, H. K. Chea, J. Drappatz, P. Y. Wen, S. P. Ivy, J. S. Loeffler, A. G. Sorensen, R. K. Jain, T. T. Batchelor. Phase Ib study of cediranib in combination with daily temozolomide and radiation in patients with newly diagnosed glioblastoma. ASCO Annual Meeting 2009. 2009.
  96. Gerstner ER, Batchelor, TT. Anti-Vascular Endothelial Growth Factor Therapy for Malignant Glioma. Current Neurology and Neuroscience Reports, in press. 2009.
  97. E. R. Gerstner, S. Yip, D. L. Wang, D. N. Louis, A. J. Iafrate, T. T. Batchelor. MGMT methylation status may predict survival in elderly patients with newly diagnosed glioblastoma (GBM). World Federation of Neuro-Oncology Meeting, Japan. 2009.
  98. T. Batchelor, A. F. Eichler, S. R. Plotkin, J. Drappatz, P. Wen, A. G. Sorensen, E. Gerstner. Phase I trial of vatalanib (PTK787) in combination with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. ASCO Annual Meeting 2009. 2009.
  99. Gerstner ER and Batchelor TT. CNS Lymphoma. In: Chiocca EA, Brem H, Sawaya R, Winn RH, editors. Youmans Textbook of Neurological Surgery: in press. 2009.
  100. T. T. Batchelor, S. Yip, D. L. Wang, D. N. Louis, A. J. Iafrate, E. R. Gerstner. MGMT methylation status may predict survival in elderly patients with newly diagnosed glioblastoma (GBM). ASCO Annual Meeting 2009. 2009.
  101. Gerstner ER, Sorensen AG, Jain R, Batchelor TT. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability and angiogenesis in gliomas. Curr Opin Neurol. 2008; 21(6):728-35.
  102. Gerstner ER, Sorensen AG, Jain RK, Batchelor TT. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol. 2008 Dec; 21(6):728-35. PMID: 18989120.
    Citations: 23     Fields:    Translation:Humans
  103. Gerstner ER, Chen PJ, Batchelor TT, Sorensen AG. Role of diffusion MRI in the detection of infiltrative glioma after treatment with cediranib. Society for Neuro-Oncology Meeting. 2008.
  104. Zhu JJ*, Gerstner ER*, Engler DA, Mruglala M, Nugent W, Nierenberg K, Hochberg FH, Betensky RA, Batchelor TT. High dose methotrexate for elderly patients with primary central nervous system lymphoma. Neuro-Oncology, Aug 29. [Epub ahead of print]. 2008.
  105. Zhu JJ, Gerstner ER, Engler DA, Mrugala MM, Nugent W, Nierenberg K, Hochberg FH, Betensky RA, Batchelor TT. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol. 2009 Apr; 11(2):211-5. PMID: 18757775.
    Citations: 24     Fields:    Translation:Humans
  106. Gerstner ER, Abrey LE, Schiff D, Ferreri AJ, Lister A, Montoto S, Tsang R, Thiel E, Graus F, Behringer D, Illerhaus G, Weaver S, Wen P, Voloschin A, Harris NL, Batchelor TT. CNS Hodgkin lymphoma. Blood. 2008 Sep 01; 112(5):1658-61. PMID: 18591379.
    Citations: 7     Fields:    Translation:Humans
  107. Gerstner E, Abrey L, Schiff D, Ferreri A, Lister A, Montoto S, Tsang R, Thiel, E, Graus F, Behringer D, Illerhaus G, Weaver S, Wen P, Voloschin A, Harris N, Batchelor T. CNS Hodgkin’s lymphoma: An International Primary CNS Lymphoma Collaborative Group (IPCG) report of 19 cases. European Hematological Association. 2008.
  108. Gerstner ER, Carson KA, Grossman SA, Batchelor TT. Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology. 2008 Jan 29; 70(5):401-2. PMID: 18227422.
    Citations: 22     Fields:    Translation:HumansCTClinical Trials
  109. Gerstner ER, Batchelor TT. Targeting VEGF signaling. In: Erwin Van Meir, editor. CNS cancer, Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. In press. 2008.
  110. Gerstner ER and Batchelor TT. Leptomeningeal Disease. In: Lisak R, Truong D, Carrol W, Bhidayasiri R, editors. International Neurology: A Clinical Approach, in press. 2008.
  111. Gerstner ER, Ryg PA, Duda DG, di Tomaso E, Loeffler JS, Sorensen G, Jain RK, Batchelor TT. Treatment of vasogenic brain edema by vascular normalization: an emerging application of anti-angiogenic agents. Nature Clinical Practice Oncology, in press. 2008.
  112. Gerstner ER and Batchelor TT. CNS Lymphoma. In: O’Brien S, Kantarjian H, Vose JM, editors. Management of Hematological Malignancies. In press. 2008.
  113. Gerstner ER, Wang DL, Batchelor TT. Molecular markers of response and resistance to vascular endothelial growth factor inhibitors in malignant glioma. 2008.
  114. Gerstner ER, Duda DG, di Tomaso E, Sorensen G, Jain RK, Batchelor TT. Antiangiogenic agents for the treatment of glioblastoma. Expert Opin Investig Drugs. 2007 Dec; 16(12):1895-908. PMID: 18041999.
    Citations: 12     Fields:    Translation:HumansAnimals
  115. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol. 2007 Jun 01; 25(16):2306-12. PMID: 17538177.
    Citations: 78     Fields:    Translation:Humans
  116. Gerstner E, Batchelor T. Primary CNS lymphoma. Expert Rev Anticancer Ther. 2007 May; 7(5):689-700. PMID: 17492932.
    Citations: 9     Fields:    Translation:Humans
  117. Gerstner E, Lazar RM, Keller C, Honig LS, Lazar GS, Marshall RS. A case of progressive apraxia of speech in pathologically verified Alzheimer disease. Cogn Behav Neurol. 2007 Mar; 20(1):15-20. PMID: 17356339.
    Citations: 8     Fields:    Translation:Humans
  118. Gerstner E, Abrey L, Schiff D, Ferreri A, Lister A, Montoto S, Tsang R, Thiel E, Graus F, Wen P, Harris N, Batchelor T. CNS Hodgkin’s lymphoma: An International Primary CNS Lymphoma Collaborative Group (IPCG) report of 13 cases. Pan Pacific Lymphoma Conference, Hawaii. 2007.
  119. Gerstner E, Abrey L, Schiff D, Ferreri A, Lister A, Montoto S, Tsang R, Thiel E, Graus F, Wen P, Harris N, Batchelor T. CNS Hodgkin’s lymphoma: An International Primary CNS Lymphoma Collaborative Group (IPCG) report of 13 cases. Society for Neuro-Oncology Meeting. 2007; EP-01.
  120. Gerstner E, Liberato B, Wright CB. Bi-hemispheric anterior cerebral artery with drop attacks and limb shaking TIAs. Neurology. 2005 Jul 12; 65(1):174. PMID: 16009921.
    Citations:    Fields:    Translation:Humans
  121. Antunes NL, Khakoo Y, Matthay KK, Seeger RC, Stram DO, Gerstner E, Abrey LE, Dalmau J. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol. 2000 Jul-Aug; 22(4):315-20. PMID: 10959901.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  122. Sciubba D and Gerstner E. Ten year old boy with recurrent parotid swelling. Office and Emergency Pediatrics. 2000; 13(5/6):195-6.
  123. Labrakakis C, Gerstner E, MacDermott AB. Adenosine triphosphate-evoked currents in cultured dorsal root ganglion neurons obtained from rat embryos: desensitization kinetics and modulation of glutamate release. Neuroscience. 2000; 101(4):1117-26. PMID: 11113360.
    Citations: 7     Fields:    Translation:AnimalsCells
  124. Voltz R, Gultekin SH, Rosenfeld MR, Gerstner E, Eichen J, Posner JB, Dalmau J. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med. 1999 Jun 10; 340(23):1788-95. PMID: 10362822.
    Citations: 54     Fields:    Translation:HumansAnimals
  125. Dalmau J, Gultekin SH, Voltz R, Hoard R, DesChamps T, Balmaceda C, Batchelor T, Gerstner E, Eichen J, Frennier J, Posner JB, Rosenfeld MR. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain. 1999 Jan; 122 ( Pt 1):27-39. PMID: 10050892.
    Citations: 33     Fields:    Translation:HumansAnimalsCells
  126. Gerstner ER, Rioult MG, Sklar E, Bear MF. Three-dimensional visualization and analysis of pyramidal cell dendrites and spines in slices of rat visual cortex. Society for Neuroscience Meeting. 1997.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Gerstner's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (299)
Explore
_
Co-Authors (101)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.